Product Description
Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens.
Mechanisms of Action: IFN Modulator
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Cutanea Life Sciences
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Rosacea|Cross Infection|Communicable Diseases|Fungemia|Bacteremia|Sepsis
Phase 2: Acne Vulgaris|Carcinoma in Situ|Dermatitis, Atopic|Rosacea|Condylomata Acuminata|Warts|Dermatitis, Seborrheic|Healthy Volunteers
Phase 1: Other|Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12618001381279p |
2006-7041-83/hah | P1 |
Withdrawn |
Other |
2018-09-19 |
|||
NCT03071679 |
CLS001-CO-PR-015 | P1 |
Completed |
Healthy Volunteers |
2017-03-07 |
2019-06-14 |
||
2017-003106-41 |
2017-003106-41 | P2 |
Completed |
Dermatitis, Seborrheic |
2020-01-06 |
2025-07-09 |
Treatments |
|
NCT03688971 |
CLS001-CO-PR-017 | P2 |
Unknown status |
Dermatitis, Seborrheic |
2019-12-01 |
48% |
2021-04-02 |
Primary Endpoints|Treatments|Trial Status |
NCT03091426 |
CLS001-CO-PR-014 | P2 |
Completed |
Dermatitis, Atopic |
2017-12-20 |
2019-06-14 |
||
2016-003849-28 |
2016-003849-28 | P2 |
Completed |
Dermatitis, Atopic |
2017-12-15 |
2025-06-29 |
Treatments |
|
2015-002724-16 |
Pharmacodynamics of omiganan in patients with usual type vulvar intraepithelial neoplasia | P2 |
Completed |
Unknown |
2017-10-15 |
2022-03-13 |
Treatments |
|
2015-005553-13 |
2015-005553-13 | P2 |
Completed |
Warts |
2017-05-11 |
2022-03-13 |
Treatments |
|
NCT02849262 |
CLS001-CO-PR-011 | P2 |
Completed |
Condylomata Acuminata |
2017-03-21 |
2019-06-14 |
Treatments |
|
2016-004702-34 |
2016-004702-34 | P2 |
Completed |
Healthy Volunteers |
2017-03-09 |
2022-03-13 |
Treatments |
|
NCT02596074 |
CLS001-CO-PR-010 | P2 |
Completed |
Carcinoma in Situ |
2017-03-07 |
2019-06-14 |
Treatments |
|
NCT02571998 |
CLS001-CO-PR-009 | P2 |
Completed |
Acne Vulgaris |
2016-08-01 |
2019-06-14 |
Treatments |
|
2014-003689-26 |
Pharmacodynamics of omiganan in patients with atopic dermatitis | P2 |
Completed |
Dermatitis, Atopic |
2015-12-16 |
2022-03-13 |
Treatments |
|
NCT01784133 |
CLS001-CO-PR-001 | P2 |
Completed |
Rosacea |
2014-03-01 |
2019-06-14 |
Treatments |
|
NCT00211523 |
A99004 | P2 |
Completed |
Acne Vulgaris |
None |
2019-03-21 |
Treatments |
|
2015-002919-15 |
2015-002919-15 | P3 |
Completed |
Rosacea |
2018-04-20 |
2025-06-28 |
Treatments |
|
2015-002921-20 |
2015-002921-20 | P3 |
Completed |
Rosacea |
2018-04-04 |
2025-07-04 |
Treatments |
|
2015-002920-23 |
2015-002920-23 | P3 |
Completed |
Rosacea |
2017-09-21 |
2022-03-13 |
Treatments |
|
NCT02576847 |
CLS001-CO-PR-006 | P3 |
Completed |
Rosacea |
2017-07-14 |
29% |
2022-07-20 |
Primary Endpoints|Start Date |
NCT02547441 |
CLS001-CO-PR-004 | P3 |
Completed |
Rosacea |
2017-07-05 |
29% |
2022-08-03 |
Primary Endpoints|Start Date|Treatments |
NCT02576860 |
CLS001-CO-PR-005 | P3 |
Completed |
Rosacea |
2017-02-27 |
2019-06-14 |
Treatments |
|
2005-003194-24 |
2005-003194-24 | P3 |
Completed |
Unknown |
2008-06-23 |
2022-03-12 |
Treatments |
|
NCT00608959 |
CPI-226-301 | P3 |
Completed |
Cross Infection|Sepsis |
2008-06-01 |
2020-05-18 |
Primary Endpoints |
|
NCT00231153 |
CPI-226-03 | P3 |
Completed |
Communicable Diseases |
2008-06-01 |
2020-05-18 |
Primary Endpoints|Treatments |
|
NCT00027248 |
NCT00027248 | P3 |
Completed |
Fungemia|Bacteremia|Sepsis |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/25/2024 |
PubMed |
Systemic therapy for psoriasis and the risk of cutaneous infections. |
|
04/10/2024 |
PubMed |
Antibacterial and Hemolytic Activity of Antimicrobial Hydrogels Utilizing Immobilized Antimicrobial Peptides. |
|
04/08/2024 |
PubMed |
Editorial: Novel biomarkers in tumor immunity and immunotherapy. |
|
05/19/2022 |
News Article |
Optimal Peptides of BOC Sciences Arouse Heated Discussions at TIDES USA 2022 |
|
03/03/2022 |
News Article |
BOC Sciences' AMPs Largely Assist Antimicrobial Therapies |